The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.

Cisplatin for injection is indicated for the treatment of advanced testicular cancer, advanced ovarian cancer, advanced bladder cancer.

Administer pre-treatment hydration and pre- and post-treatment antiemetics. Cisplatin for injection has been administered intravenously at: Advanced testicular cancer: 20 mg/m2 daily for 5 days 2 per cycle; Advanced ovarian cancer: 75 mg/m2 to 100 mg/m2 per cycle once every 3 to 4 weeks; Advanced bladder cancer: 50 mg/m2 to 70 mg/m2 intravenously per cycle once every 3 to 4 weeks. Refer to current treatment guidelines for specific dosing information. Administer by slow intravenous infusion. Avoid contact of cisplatin for injection with aluminum parts.

Common adverse reactions are nephrotoxicity, peripheral neuropathy, nausea and vomiting, myelosuppression, and ototoxicity.

Cisplatin for injection is contraindicated in patients with severe hypersensitivity to cisplatin.

Hypersensitivity reactions: Anaphylaxis and death may occur; monitor for and treat accordingly. Ototoxicity: Cumulative toxicity may be severe particularly in pediatric patients; consider audiometric and vestibular function monitoring. Ocular toxicity: Optic neuritis, papilledema, and cortical blindness may occur. Secondary leukemia: Secondary acute leukemia may occur. Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.